Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4634 Management of hypercalcaemia of malignancy in neuroendocrine tumour patients – A case series

Introduction: Hypercalcaemia of malignancy (HM) rarely coexists with neuroendocrine tumours (NET). There are no precise guidelines for management of hypercalcaemia in NET.

Conference:

Presenting Author:

Authors: Klepinowska M, Sagan K, Brzeska A, Andrysiak-Mamos E, Kiedrowicz B,

Keywords: hypercalcaemia of malignancy, neuroendocrine tumour, pancreatic neuroendocrine tumour, hypercalcaemia,

#4518 Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602)

Introduction: Well-differentiated G3 NETs have been described as a distinct category recently, and randomised data regarding efficacy of therapy are scarce. In the phase 3 CABINET trial (NCT03375320), CABO significantly prolonged progression-free survival (PFS) compared with placebo (PB) in patients (pts) with advanced, previously treated, progressive well-differentiated extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades (Chan et al., NEJM, 2024).

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Zemla T, Geyer S, Pulsipher S, Behr S,

Keywords: cabozantinib, grade 3 neuroendocrine tumour, pancreatic neuroendocrine tumour, extra-pancreatic neuroendocrine tumour,

#4445 Pancreatico-duodenal gastrinomas: Surgical management and late results – 50 years' experience in a single centre

Introduction: Gastrinomas are one of the less frequent and elusive variety of neuroendocrine tumours (NET) of the upper digestive tract and pancreas, clinically expressed with a Zollinger-Ellison syndrome (ZES), possibly associated to a Multiple Endocrine Neoplasia type 1 (MEN1).

Conference:

Presenting Author:

Authors: Milanetto A, Veronese E, de Carlo E, Pasquali C,

Keywords: gastrinoma, men1, net,

#3863 Survival and prognostic factors in appendiceal neuroendocrine tumors (ANET) and goblet cell carcinoma (aGCC)

Introduction: Appendiceal goblet cell carcinomas (aGCC) present with overlapping features of appendiceal neuroendocrine neoplasms (ANET) and adenocarcinomas. A previous study found that ANET with peritoneal metastases have a 5-year survival rate of 7%. Recent studies show that ANET rarely metastasizes, contrary to aGCC. The latest WHO classification excluded aGCC from the group of NETs and classified it as appendiceal adenocarcinomas.

Conference:

Presenting Author: Dijke K

Authors: Dijke K, Levy S, van den Berg J, Tesselaar M,

Keywords: Goblet cell carcinoma, Appendiceal neuroendocrine tumor, Survival,